26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
September 2021
in “Journal of The American Academy of Dermatology”
TLDR Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
The phase 2 of the BRAVE-AA1 study evaluated the effectiveness of baricitinib, a JAK1/JAK2 inhibitor, in treating alopecia areata (AA) patients. The study involved 82 participants divided into three groups: baricitinib 4-mg (27 participants), baricitinib 2-mg (27 participants), and placebo (28 participants). At week 36, 52% of the 4-mg group, 33% of the 2-mg group, and 4% of the placebo group achieved a Severity of Alopecia Tool (SALT) score ≤20, indicating hair regrowth. In terms of eyebrow and eyelash improvement, 39% and 60% of the 4-mg group, 29% and 40% of the 2-mg group, and 4% and 6% of the placebo group achieved eyebrow and eyelash scores ≤1, respectively. These results suggest that baricitinib may be an effective treatment for AA.
View this study on jaad.org →
Related
research Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Alopecia Areata After Severe Allergic Contact Dermatitis to a Permanent Hair Dye
A 24-year-old male with a history of henna tattoo reaction developed alopecia areata (AA) following severe allergic contact dermatitis (ACD) from a black hair dye. Patch tests revealed strong reactions to p-phenylenediamine (PPD) and related compounds. Treatment with corticosteroids and minoxidil led to hair regrowth within 5 months. Two years later, the patient was diagnosed with multiple sclerosis (MS), a rare co-morbidity of AA. This case suggests that ACD can trigger AA in predisposed individuals, potentially due to interactions among inflammatory pathways. The study highlights the importance of considering ACD as a trigger for AA and the possible association between AA and MS.
research 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
research Rare Presentation of Concomitant Alopecia Areata and Vitiligo in a Teenager
research Hair Loss in Lichen Planopilaris and Frontal Fibrosing Alopecia: Not Always Irreversible
Hair loss from conditions like LPP and FFA can potentially be reversed with the right treatment.
research Hair disorders
The document's conclusion cannot be provided because the document cannot be parsed.
research Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia
Bimatoprost is promising for treating some types of hair loss but needs more testing for androgenetic alopecia.